812 related articles for article (PubMed ID: 32819390)
21. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.
Iveson T
Curr Opin Oncol; 2020 Jul; 32(4):370-376. PubMed ID: 32541327
[TBL] [Abstract][Full Text] [Related]
23. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
24. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.
Sunami E; Kusumoto T; Ota M; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Okabe M; Tanaka C; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Takenaka N; Okude R; Sugihara K
Clin Colorectal Cancer; 2020 Mar; 19(1):22-31.e6. PubMed ID: 31917122
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
26. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
Yekedüz E; Köksoy EB; Akbulut H; Ürün Y; Utkan G
Future Oncol; 2021 Jan; 17(3):349-357. PubMed ID: 33356539
[No Abstract] [Full Text] [Related]
27. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
[TBL] [Abstract][Full Text] [Related]
28. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
29. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
Sobrero A; Grothey A; Iveson T; Labianca R; Yoshino T; Taieb J; Maughan T; Buyse M; André T; Meyerhardt J; Shields AF; Souglakos I; Douillard JY; Cervantes A
Ann Oncol; 2018 May; 29(5):1099-1107. PubMed ID: 29438451
[TBL] [Abstract][Full Text] [Related]
30. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
31. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
[TBL] [Abstract][Full Text] [Related]
32. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
[TBL] [Abstract][Full Text] [Related]
33. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
[TBL] [Abstract][Full Text] [Related]
35. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
37. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
38. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
39. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
[TBL] [Abstract][Full Text] [Related]
40. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.
Daamen LA; van Goor IWJM; Groot VP; Andel PCM; Brosens LAA; Busch OR; Cirkel GA; Mohammad NH; Heerkens HD; de Hingh IHJT; Hoogwater F; van Laarhoven HWM; Los M; Meijer GJ; de Meijer VE; Pande R; Roberts KJ; Stoker J; Stommel MWJ; van Tienhoven G; Verdonk RC; Verkooijen HM; Wessels FJ; Wilmink JW; Besselink MG; van Santvoort HC; Intven MPW; Molenaar IQ;
Trials; 2024 Jun; 25(1):401. PubMed ID: 38902836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
